Biome Lift Clinical Trial Presentation
Released
Released
Announcement PDF
6th July 2023
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
Results from the
Biome LiftTM Study
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
Biome Lift Probiotic
PAGE
2
To support healthy mood balance and enhance
sleep quality
May help reduce cognitive fatigue
Clinically trialled formulation
Microbac™ technology: 5x more effective delivery
3
PAGE
Practitioner-only probiotics
Biome Lift™ Probiotic
FORMULATION
PRACTITIONER-ONLY PRODUCT
Lactobacillus plantarum LP01 (LMG P-21021)
1 BLB*
Lactobacillus rhamnosus LR06 (DSM 21981)
1 BLB*
Bifidobacterium longum 04 (DSM 23233)
1 BLB*
Lactobacillus fermentum LF16 (DSM 26956)
1 BLB*
Total live bacteria
4 BLB*
*BLB = Billion Live Bacteria
ACTIVATEDPROBIOTICS.COM.AU
Guaranteed potency
Gut-brain axis
The gut-brain axis refers to the bidirectional
communication between the gut and the brain.
It involves complex interrelationships between
many biological systems, including:
●
The gastrointestinal system
●
The nervous system
●
The immune system
●
The endocrine system
●
The circulatory system
Practitioner-only probiotics
Of recent interest is the gut-microbiota-brain axis
which considers the coordinating and modulatory
role of the ‘microbial system’.
This concept encompasses the direct and indirect
communication between gut bacteria and the brain
through the human’s biological channels.
Toribio-Mateas, M. (2018). Harnessing the Power of Microbiome Assessment Tools as Part of
Neuroprotective Nutrition and Lifestyle Medicine Interventions. Microorganisms, 6(2), 35.
ACTIVATEDPROBIOTICS.COM.AU
PAGE
4
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
Previous studies
PAGE
5
Results of
the first study
First trial examining the effects of the formulation in
Biome Lift Probiotic-
Results from the Profile of Mood State and
Pittsburgh Sleep Quality Index found that using
this probiotic formula in a healthy population
significantly improved:
●
Sleep quality and mood
●
Depressive feelings
●
Anger-hostility
●
Fatigue
Probiotic
Practitioner-only probiotics
Marotta A, Sarno E, Casale A Del, Pane M, Mogna
L, Amoruso A, et al.
Effects of probiotics on cognitive reactivity,
mood, and sleep quality.
Front Psychiatry. 2019;10(164):1–11.
Placebo
Median Profile of Mood States (POMS) depression subscale score from the
participants in the probiotic group and the placebo group. Error bars represent
95% confidence intervals. Asterisks indicate within-group significant
differences (Bonferroni corrected p<0.017).
ACTIVATEDPROBIOTICS.COM.AU
PAGE
6
Results of
the second study
Beck Depression Inventory (BDI)
Psychometric test to measure depression
Second trial examining the effects of the formulation in
Biome Lift ProbioticC. Kerksick, R. Jäger, et al. Multi-strain probiotic
supplementation increases sleep quality, mood and
neurotransmitter levels.
Practitioner-only probiotics
Positive findings for improved depressive mood and
symptoms of anxiety using:
●
Beck Depression Inventory
●
Leiden Index of Depression-Sensitivity
●
Life Orientation Test
●
State Trait Anxiety Inventory
Confirmed Marotta’s previous findings of improved
sleep quality using Pittsburgh Sleep Quality Index.
Found increases in serum serotonin levels.
ACTIVATEDPROBIOTICS.COM.AU
PAGE
7
8
PAGE
These findings are the culmination of a strategic research
partnership with La Trobe University and help to strengthen
the existing clinical evidence of efficacy for Biome LiftTM
Probiotic.
Practitioner-only probiotics
Biome Australia Limited has received the pre-publication
results of the Biome LiftTM Probiotic clinical trial taking place
at La Trobe University in Melbourne.
ACTIVATEDPROBIOTICS.COM.AU
The Biome Lift Study
9
PAGE
Practitioner-only probiotics
The study hypothesized that the probiotic experimental
group would experience a reduction in the severity of
depressive symptoms compared to the control group
receiving a placebo, and that this would be mediated by
beneficial changes in gut microbiota composition and a
consequent production of precursors of neuroactive
substances that impact oxidation and inflammatory
pathways (demonstrated by improved levels of inflammation
and oxidative stress markers).
ACTIVATEDPROBIOTICS.COM.AU
The hypothesis
The primary outcome measure: the subjective assessment of depression using the following validated questionnaire: Beck Depression
Inventory 2nd edition (BDI-II; self-report, brief specifically measures characteristic attitudes and symptoms of depression) [4 timepoints at pre,
mid, post and follow-up]
Secondary aims were to assess:
i) the efficacy of the Biome Lift™ Probiotic compared with a placebo in delivering an improvement in quality of life and other measures of
psychosocial health (i.e., anxiety, stress, mood) in subjects with subthreshold depression;
ii) the effects of the Biome Lift™ Probiotic on blood and saliva biomarkers of inflammatory, immune and stress response;
iii) the effects of the Biome Lift™ Probiotic on gut microbiota composition and function;
iv) the effects of the Biome Lift™ Probiotic on anthropometric and body composition markers; and,
v) the effects of the Biome Lift™ Probiotic on gastrointestinal health (gut symptom severity).
PAGE 10
Practitioner-only probiotics
Primary aim: to assess the efficacy of the Biome Lift™ Probiotic compared with a placebo in reducing the severity of depressive symptoms in
patients with subthreshold depression.
ACTIVATEDPROBIOTICS.COM.AU
Study aims and outcome measures
1. Subjective and clinical assessment of depression, anxiety, mood and QoL, using the following validated questionnaires:
●
Patient Health Questionnaire (PH9; self-report, brief specifically measures depression and has been shown to be responsive to
intervention) [weekly]
●
Structured Clinical Interview for DSM-5 (SCID 5; clinically administered; depression symptoms) [pre and post only]
●
Hospital Anxiety and Depression Scale (HADS; clinically administered; anxiety and depression) [4 timepoints at pre, mid, post and
follow-up]
●
Depression, Anxiety and Stress Scale (DASS-21; self-report; depression, anxiety and stress severity ratings) [4 timepoints at pre, mid,
post and follow-up]
●
Assessment of Quality of Life (AQOL-8; self-report; health-related quality of life) [4 timepoints at pre, mid, post and follow-up]
●
Perceived Stress Scale (PSS; self-report; stress perception measurement) [4 timepoints at pre, mid, post and follow-up]
●
Covid-19 impact tool (self-report; stress perception measurement) [4 timepoints at pre, mid, post and follow-up]
2. A range of inflammatory, immune and metabolic biomarkers assessed via blood samples including: fasting plasma glucose, serum insulin,
HOMA-IR, hs-CRP and total GSH
3. Gut microbiota composition changes assessed via fecal samples testing for microbiota genome and functional predictions of gut microbiota [3
timepoints at pre, mid and post]
4. Salivary cortisol as a biomarker of stress assessed via saliva sample collection [3 timepoints at pre, mid and post]
5. Subjective assessment of gastrointestinal health using the following validated questionnaire: Irritable bowel syndrome-severity scoring system
(IBS-SSS; self-report; gut symptom severity) [4 timepoints at pre, mid, post and follow-up]
PAGE 11
Practitioner-only probiotics
The secondary outcome measures are as followed:
ACTIVATEDPROBIOTICS.COM.AU
Study aims and outcome measures
PAGE 12
The study was a double-blind randomised parallel group clinical trial of probiotic supplementation versus placebo
in a 1:1 ratio in patients diagnosed with subthreshold depression. The probiotic or placebo supplementation was
taken daily for 3-months.
Completed intervention (n=30)
Randomized (n=39)
Assessed for eligibility
(n=912)
N=19
ACTIVATEDPROBIOTICS.COM.AU
N=20
Practitioner-only probiotics
Study design
Interested participants had to meet the diagnosis of subthreshold depression, via a screening interview with the study psychologist, using the
Structured Clinical Interview for DSM-5 (SCID 5).
Sub-threshold depression is defined as:
●
Exhibiting at least 1 of the 2 core symptoms* for depression, as well as one other symptom^, but not meeting the 5 or more
symptoms required for a diagnosis of unipolar major depression, albeit, in general 2 to 4 symptoms of those seen in a depressive
episode are present); and,
●
Who are not undergoing any pharmacological or psychological treatment.
PAGE 13
Practitioner-only probiotics
Definition of subthreshold depression
*Core Symptoms
1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad, empty, hopeless) or observation made by others (e.g., appears tearful);
2. Markedly diminished interest or pleasure in all or almost all activities most of the day, nearly every day (as indicated by either subjective account or observation made by others);
^Other Symptoms
3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day;
4. Insomnia or hypersomnia nearly every day;
5. Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down);
6. Fatigue or loss of energy nearly every day;
7. Feeling of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick);
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others);
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.
ACTIVATEDPROBIOTICS.COM.AU
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), symptoms for subthreshold depression must be
experienced during a period of at least 2 weeks before diagnosis.
PAGE 14
Exclusion Criteria
∙
Male and female adults
•
Suicidal ideation, with or without a specific plan
∙
Aged between 18 and 65 y
•
Comorbidity with substance use disorders or organic mental disorders
∙
Not in the underweight category (BMI ≥18.5 kg/m2)
•
Neurological conditions affecting the brain, other central functions or any
other mental health condition (i.e., psychosis, eating disorder)
∙
Meet the criteria for subthreshold depression
•
∙
Have not been taking antidepressants /other medications acting on the CNS
/psychological treatment (eg, cognitive behavioral therapy) for at least 6
weeks
Organic comorbidities (i.e., gastrointestinal, or autoimmune or chronic
inflammatory conditions)
•
Nutritional supplement use (vitamins, minerals or antioxidants)
•
Antibiotic use in the six weeks before the start of the trial participation
•
Pregnant or breastfeeding.
∙
Are able to understand and thus correctly fill in the questionnaires required
as part of the study protocol.
Practitioner-only probiotics
Inclusion Criteria
ACTIVATEDPROBIOTICS.COM.AU
Inclusion criteria
Study participant flow
diagram
Figure 2 presents the CONSORT flow diagram of study
participants.
Baseline characteristics
Table 2 summarises the descriptive
characteristics of study participants, in
terms of socio-demographics and
anthropometrics, in the total sample (n=39)
and by treatment arm.
The non-existence of differences in almost all of the
examined socio-demographic and anthropometric
indices presented in Table 2, indicates homogeneity
of the study sample at baseline. This is pivotal in
RCTs, since homogeneity of the study sample
reflects the validity of randomization, which
increases the quality of the study.
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
Pre-publication results
PAGE 17
Results from the self-report questionnaires provide evidence on the effectiveness of the Biome Lift intervention in reducing the severity of
depressive symptoms in patients with subthreshold depression. According to these findings, although there were no differences observed
between the two groups, there were several within-group changes that were primarily in favour of the probiotic group.
In a follow-up subgroup of the original cohort, improvements observed in the probiotic group in terms of depressive and anxiety symptoms (i.e.,
through the greater reductions seen in BDI HADS-A, HADS-D total scores) at the end of the intervention, also remained 6 weeks
post-intervention.
The blood results clearly indicate a reduction in inflammation (i.e., through the reduction in hs-CRP levels) in the probiotic arm, as well as an
improvement in brain antioxidant capacity (i.e., through the increases observed in total glutathione levels) both at 6 and 12 weeks of treatment.
PAGE 18
Practitioner-only probiotics
Results summary
According to the faecal analysis, there were no differences or trends observed between timepoints or treatment arms for gut microbiome
diversity measures.
The non-existence of between-group differences or within-group changes in anthropometric indices during the intervention is a positive finding,
since this means that there is no confounding effect of weight status on the study outcomes.
The non-existence of between-group differences or within-group changes for the vast majority of dietary intake indices during the intervention
is a positive finding, since this means that they had confounding effect on the study outcomes. The significant findings observed for energy,
protein and especially dietary fibre (which has a prebiotic effect) might need to be taken into consideration on future statistical analyses of
study outcomes.
ACTIVATEDPROBIOTICS.COM.AU
The saliva results clearly indicate a reduction in stress levels (i.e., through the reduction in 30 minutes post-awakening cortisol and cortisol
awakening response levels) in the probiotic arm, compared to the placebo after 12 weeks.
Questionnaire results
Table 5 summarises the within-group changes and between-group
differences in the examined depression, mood, anxiety, stress and
quality of life scores that were assessed throughout the 12-month
intervention period, via the administered self-report questionnaires.
The figures on slides 20-25 present the results from the
questionnaires that demonstrated statistically significant
within-group changes only, except for the total HADS score.
The results presented in Table 5 provide evidence on the effectiveness of the
Biome Lift intervention in reducing the severity of depressive symptoms in
patients with subthreshold depression. According to these findings, although
there were no differences observed between the two groups, there were several
within-group changes that were primarily in favour of the probiotic group. This is a
common finding stemming from other relevant small-scale studies that examine
similar depressive symptoms related outcomes. In addition, our study, but also
other similar studies, indicate a potential “placebo effect” on the examined
outcomes. This is something that is expected, considering the subjective nature
of the data collected through the administered questionnaires and the fact that
people tend to report feeling better when receiving a treatment, even if this is just
a placebo.
% improvement
The Beck Depression Inventory 2nd edition (BDI-II) is
designed to assess presence and severity of depressive
symptoms.
Figure 1: Changes in mean (95% CI) of BDI total scores
*p < 0.05, significant within-group change from baseline to
follow-up.
The probiotic group significantly decreased their BDI
total score by -6.5 (95% CI -12.3; -0.7) and -7.6 (95%
CI -13.4; -1.8) at 6 and 12 weeks of intervention
respectively.
A significant decrease of -6.6 (95% CI -12.1; -1.1) was
also observed in the placebo group, but only at the
end of the 12-week intervention.
PAGE 20
Practitioner-only probiotics
BECK DEPRESSION INVENTORY 2nd EDITION
ACTIVATEDPROBIOTICS.COM.AU
Questionnaire-Based Assessment Tools
Practitioner-only probiotics
The Patient Health Questionnaire (PH9) is a self-report
questionnaire that specifically measures depression.
Figure 2: Changes in mean (95% CI) PHQ total scores
*p < 0.05, significant within-group change from baseline
to follow-up.
The PHQ total score decreased significantly by -4.2
(95% CI -7.1; -1.3) and -4.1 (95% CI -7.0; -1.2) in
the probiotic group and by -2.5 (95% CI -4.9; -0.006)
and -3.2 (95% CI -5.7; -0.7) in the placebo group
after 6 and 12 weeks of intervention respectively.
ACTIVATEDPROBIOTICS.COM.AU
% improvement
PATIENT HEALTH QUESTIONNAIRE 9
PAGE 21
Questionnaire-Based Assessment Tools
HADS ANXIETY SUBSCALE (HADS-A)
PAGE 22
Figure 3: Changes in mean (95% CI) HADS-A total scores
*p < 0.05, significant within-group change from baseline
to follow-up.
The HADS-A total score decreased significantly only
in the probiotic group by -2.8 (95% CI -5.2; -0.4) and
-2.7 (95% CI -5.1; -0.3) at 6 and 12 weeks of
intervention respectively.
The decrease in the HADS-A score for the probiotic
group was borderline significantly higher compared
to the decreases observed in the placebo group
(P=0.059).
ACTIVATEDPROBIOTICS.COM.AU
% improvement
The Hospital Anxiety and Depression Scale (HADS)
measures anxiety and depression.
Practitioner-only probiotics
Questionnaire-Based Assessment Tools
Practitioner-only probiotics
Figure 4: Changes in mean (95% CI) HADS-D total scores
*p < 0.05, significant within-group change from baseline to
follow-up.
The HADS-D total score decreased significantly only
in the probiotic group by -3.0 (95% CI -5.4; -0.7) and
-2.5 (-4.9; -0.2) at 6 and 12 weeks of intervention
respectively.
ACTIVATEDPROBIOTICS.COM.AU
% improvement
HADS DEPRESSION SUBSCALE (HADS-D)
PAGE 23
Questionnaire-Based Assessment Tools
Practitioner-only probiotics
The Depression, Anxiety and Stress Scale (DASS-21)
provides separate severity ratings for depression, anxiety
and stress.
Figure 5: Changes in mean (95% CI) DASS-D total scores
*p < 0.05, significant within-group change from baseline to
follow-up.
The DASS-D total score also decreased
significantly in the probiotic group by -2.2 (95% CI
-4.3; -0.04), at the 6 weeks of intervention mark
ACTIVATEDPROBIOTICS.COM.AU
% improvement
DASS-21 DEPRESSION SUBSCALE (DASS-D)
PAGE 24
Questionnaire-Based Assessment Tools
Figure 6: Changes in mean (95% CI) DASS-S total scores
*p < 0.05, significant within-group change from baseline
to follow-up.
The DASS-S total score decreased significantly
only in the placebo group by -2.1 (95% CI -4.0; -0.1)
after the 12-week intervention
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
DASS-21 STRESS SUBSCALE (DASS-S)
PAGE 25
Questionnaire-Based Assessment Tools
As per the results in Table 3 and
considering that changes (especially
increases) in weight status/body size can
be associated with changes in mood,
anxiety and stress levels, the
non-existence of between-group
differences or within-group changes in
anthropometric indices during the
intervention is a positive finding, since this
means that there is no confounding effect
of weight status on the study outcomes.
PAGE 26
Practitioner-only probiotics
Table 3 illustrates the changes observed in body weight and body mass index from baseline to the follow-up points (i.e.,
at 6 and 12 weeks), the changes within each treatment arm as well as the differences between them.
ACTIVATEDPROBIOTICS.COM.AU
Anthropometrics data
Dietary intake data
The within-group changes observed in dietary
energy and macronutrients’ intake from baseline to
follow-up time points, as well as the between-group
differences are summarised in Table 4.
A 24-hour food recall diary was used to assess significant
changes in diet intake across the study period. According to
the data in Table 4 and as dietary intake can also affect gut
microbiota composition, the non-existence of between-group
differences or within-group changes for the vast majority of
dietary intake indices during the intervention is a positive
finding, since this means that there is no confounding effect
of dietary intake (at least for all those nutrients where no
significant changes/differences were reported) on the study
outcomes. However, the significant findings observed for
energy, protein and especially dietary fibre (which has a
prebiotic effect) might need to be taken into consideration on
future statistical analyses of study outcomes.
6 week follow-up
Table 6 presents the within-group changes and
between-group differences in the examined
depression, mood, anxiety, stress, and quality of life
scores from baseline to the 18-week follow-up
time-point (i.e., 6 weeks post-intervention).
The results presented in Table 6 indicate that the improvements
observed in the probiotic group in terms of depressive and
anxiety symptoms (i.e., through the greater reductions seen in
BDI HADS-A, HADS-D total scores) at the end of the
intervention, also remained 6 weeks post-intervention. As this
post-intervention survey was optional, data was received from
10 and 9 participants in the probiotic and the placebo group.
Despite these numbers and the fact that an intention-to-treat
analyses could not be performed, these significant changes are
very important since they are indicative of the longer-term
effectiveness of the probiotic supplement. Although, not
statistically significant and with the only exception of the
DASS-A, the changes (reductions) in all other scores were also
in favour of the probiotic group.
Blood analysis
Table 7 presents the within-group changes and
between-group differences in fasting plasma
glucose, serum insulin, HOMA-IR (i.e. a biomarker
of insulin resistance), serum high-sensitivity CRP
(i.e., a marker of inflammation) and total
glutathione concentrations (i.e., a peptide with
antioxidant/protective properties, especially in brain
cells).
The results presented in Table 7 clearly indicate a reduction
in inflammation (i.e., through the reduction in hs-CRP levels)
in the probiotic arm, as well as an improvement in brain
antioxidant capacity (i.e., through the increases observed in
total glutathione levels) both at 6 and 12 weeks of treatment.
The significant differences that were observed between the
probiotic compared to the placebo arm further support the
anti-inflammatory and antioxidant properties (especially in the
brain cells) of the probiotic supplement, which also “back-up”
the favourable changes observed in the depression and
anxiety scores.
Saliva analysis
Table 8 summarizes the within-group
changes and between-group differences in
saliva cortisol levels (i.e., as stress
biomarker) at awakening (S1), 30-minutes
post-awakening (S2) and in the evening at
2030 hours (S3), as well as in the Cortisol
Awakening Response (CAR), which
represents the normally occurring increase
in cortisol levels after awakening and has
been positively related to stress.
The results presented in Table 8 clearly indicate a
reduction in stress levels (i.e., through the reduction
in S2 cortisol and CAR levels) in the probiotic arm,
compared to the placebo at the end of the 12-week
intervention period. These findings also support the
favourable changes observed in the depression and
anxiety scores coming from the questionnaires.
Faecal analysis
Figures 10 and 11 graphically present the
gut microbiome diversity measures by
timepoint (i.e., baseline, 6-week and
12-week follow-up) and treatment arm (i.e.,
probiotic and placebo) respectively.
According to these figures there were no
differences or trends observed between timepoints
or treatment arms. The effects of the Biome Lift™
Probiotic on gut microbiota composition and
function were a secondary aim of the study, and
these results suggest that the improvements
observed in depression and anxiety scores may not
be mediated by changes to the gut microbiota.
ACTIVATEDPROBIOTICS.COM.AU
Practitioner-only probiotics
Thank You
Share your feedback
Discover